Trial reportDrug design, development and therapy2025
Efficacy of Different Doses of Remimazolam Tosilate Combined with Esketamine in Painless Abortion Patients: A Prospective, Double-Blind, Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The median effective dose (EDBMC anesthesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Remimazolam tosilate (RT) is a novel ultra-short-acting benzodiazepine with rapid onset, short half-life, stable hemodynamics, and minimal respiratory depression. This study aimed to assess the efficacy, safety, and optimal dosage of RT combined with esketamine for painless abortion procedures. Methods: This single-center, prospective, randomized, double-blind trial was conducted from December 2022 to December 2024. A total of 210 patients (aged 18-45 years, ASA I-II, BMI 18-28 kg/m Results: The ΔMAP in Group RL (7.11 ± 2.49) was significantly lower than in Group P (11.93 ± 2.09) and Group RH (12.80 ± 2.59) (F = 114.286, Conclusion: Low-dose RT (0.2 mg/kg) combined with esketamine significantly shortens recovery and discharge times, ensures hemodynamic stability, and reduces adverse events, making it the recommended sedation strategy for painless abortion procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.